A drug that can slow early Alzheimer’s by up to 60 per cent has been hailed as the ‘turning point’ in the fight against the disease.In a ‘defining moment’ for dementia research, results from trials of donanemab found it significantly delayed the worsening of symptoms in people with this type of dementia.to offer hope to patients in what experts have hailed ‘the decade of Alzheimer’s’, which could one day see it likened to other long-term conditions such as asthma or .
Load More
Load More